Detailed information for compound 434444
Basic information
Technical information
- TDR Targets ID: 434444
- Name: methyl N-[6-[4-[(3-ethylphenyl)carbamoylamino ]phenoxy]-1H-benzimidazol-2-yl]carbamate
- MW: 445.471 | Formula: C24H23N5O4
-
H donors: 4
H acceptors: 3
LogP: 4.29
Rotable bonds: 10
Rule of 5 violations (Lipinski): 1 - SMILES: COC(=O)Nc1nc2c([nH]1)cc(cc2)Oc1ccc(cc1)NC(=O)Nc1cccc(c1)CC
- InChi: 1S/C24H23N5O4/c1-3-15-5-4-6-17(13-15)26-23(30)25-16-7-9-18(10-8-16)33-19-11-12-20-21(14-19)28-22(27-20)29-24(31)32-2/h4-14H,3H2,1-2H3,(H2,25,26,30)(H2,27,28,29,31)
- InChiKey: IDBPJJQGJZOVMW-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- N-[6-[4-[[(3-ethylanilino)-oxomethyl]amino]phenoxy]-1H-benzimidazol-2-yl]carbamic acid methyl ester
- N-[6-[4-[(3-ethylphenyl)carbamoylamino]phenoxy]-1H-benzimidazol-2-yl]carbamic acid methyl ester
- N-[6-[4-[[[(3-ethylphenyl)amino]-oxomethyl]amino]phenoxy]-1H-benzimidazol-2-yl]carbamic acid methyl ester
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | kinase insert domain receptor | Starlite/ChEMBL | References |
| Homo sapiens | TEK tyrosine kinase, endothelial | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
| Species | Potential target | Known druggable target/s | Ortholog Group |
|---|---|---|---|
| Loa Loa (eye worm) | TK/KIN16 protein kinase | Get druggable targets OG5_130320 | All targets in OG5_130320 |
| Brugia malayi | Immunoglobulin I-set domain containing protein | Get druggable targets OG5_130320 | All targets in OG5_130320 |
| Onchocerca volvulus | Get druggable targets OG5_130320 | All targets in OG5_130320 | |
| Onchocerca volvulus | Tyrosine kinase homolog | Get druggable targets OG5_130320 | All targets in OG5_130320 |
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0127 | 0.6734 | 0.5 |
| Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0127 | 0.6734 | 0.5 |
| Plasmodium vivax | RNA helicase-1, putative | 0.0127 | 0.6734 | 0.5 |
| Echinococcus granulosus | defective proboscis extension response | 0.0011 | 0.0021 | 0.0031 |
| Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0127 | 0.6734 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0399 | 0.0399 |
| Echinococcus multilocularis | Immunoglobulin | 0.0011 | 0.0021 | 0.0031 |
| Echinococcus multilocularis | Immunoglobulin | 0.0011 | 0.0021 | 0.0031 |
| Leishmania major | eukaryotic initiation factor 4a, putative | 0.0127 | 0.6734 | 0.5 |
| Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0127 | 0.6734 | 1 |
| Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0127 | 0.6734 | 0.5 |
| Schistosoma mansoni | vesicular amine transporter | 0.0011 | 0.0021 | 0.0031 |
| Echinococcus multilocularis | basement membrane specific heparan sulfate | 0.0011 | 0.0021 | 0.0031 |
| Schistosoma mansoni | nephrin | 0.0018 | 0.0438 | 0.065 |
| Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0127 | 0.6734 | 0.5 |
| Echinococcus granulosus | neurotracting:lsamp:neurotrimin:obcam | 0.0015 | 0.0233 | 0.0346 |
| Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0127 | 0.6734 | 0.5 |
| Echinococcus granulosus | twitchin | 0.0014 | 0.0187 | 0.0277 |
| Schistosoma mansoni | cell adhesion molecule | 0.0019 | 0.0484 | 0.0718 |
| Echinococcus multilocularis | roundabout 2 | 0.0022 | 0.065 | 0.0964 |
| Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0233 | 0.0233 |
| Leishmania major | eukaryotic initiation factor 4a, putative | 0.0127 | 0.6734 | 0.5 |
| Brugia malayi | hypothetical protein | 0.0016 | 0.0272 | 0.0272 |
| Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.6734 | 0.6734 |
| Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0272 | 0.0272 |
| Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0127 | 0.6734 | 0.5 |
| Schistosoma mansoni | defective proboscis extension response (dpr)-related | 0.0011 | 0.0021 | 0.0031 |
| Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0399 | 0.0399 |
| Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0184 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0021 | 0.0021 |
| Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0127 | 0.6734 | 1 |
| Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0016 | 0.0272 | 0.0272 |
| Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0127 | 0.6734 | 0.5 |
| Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0127 | 0.6734 | 1 |
| Onchocerca volvulus | Tyrosine kinase homolog | 0.0172 | 0.9305 | 1 |
| Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0127 | 0.6734 | 1 |
| Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0127 | 0.6734 | 1 |
| Echinococcus granulosus | Immunoglobulin | 0.0011 | 0.0021 | 0.0031 |
| Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0021 | 0.0021 |
| Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0021 | 0.0021 |
| Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0127 | 0.6734 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0272 | 0.0272 |
| Treponema pallidum | ATP-dependent RNA helicase | 0.0127 | 0.6734 | 0.5 |
| Echinococcus granulosus | neuroglian | 0.0014 | 0.0187 | 0.0277 |
| Brugia malayi | eukaryotic initiation factor 4A | 0.0127 | 0.6734 | 0.6734 |
| Echinococcus granulosus | roundabout 2 | 0.0022 | 0.065 | 0.0964 |
| Echinococcus multilocularis | neuroglian | 0.0014 | 0.0187 | 0.0277 |
| Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0272 | 0.0272 |
| Brugia malayi | Fibronectin type III domain containing protein | 0.0016 | 0.0272 | 0.0272 |
| Onchocerca volvulus | 0.0167 | 0.9006 | 0.8838 | |
| Schistosoma mansoni | Neurotrimin precursor (hNT) | 0.0011 | 0.0021 | 0.0031 |
| Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0127 | 0.6734 | 0.5 |
| Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0127 | 0.6734 | 1 |
| Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0127 | 0.6734 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| AC50 (binding) | = uM | GSK_PKIS: Inhibition of Sea Pansy Luciferase (Data from PubChem: AID 652015) [NIH NCATS] | ChEMBL. | No reference |
| AC50 (binding) | = 32.609 uM | GSK_PKIS: Inhibition of Firefly Luciferase (Data from PubChem: AID 652016) [NIH NCATS] | ChEMBL. | No reference |
| IC50 (binding) | = 2.9 nM | Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus | ChEMBL. | 17676829 |
| IC50 (binding) | = 2.9 nM | Inhibition of GST-tagged human recombinant VEGFR2 expressed in baculovirus | ChEMBL. | 17676829 |
| IC50 (binding) | = 18 nM | Inhibition of GST-tagged human recombinant TIE2 expressed in baculovirus | ChEMBL. | 17676829 |
| IC50 (binding) | = 18 nM | Inhibition of GST-tagged human recombinant TIE2 expressed in baculovirus | ChEMBL. | 17676829 |
| IC50 (binding) | = 170 nM | Inhibition of TIE-2/c-fms chimeric protein expressed in mouse 3T3 cells assessed as autophosphorylation level by ELISA | ChEMBL. | 17676829 |
| IC50 (binding) | = 170 nM | Inhibition of TIE-2/c-fms chimeric protein expressed in mouse 3T3 cells assessed as autophosphorylation level by ELISA | ChEMBL. | 17676829 |
| Inhibition (binding) | = -17 % | GSK_PKIS: IKK-alpha % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = -14.13 % | GSK_PKIS: SPHK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -13.04 % | GSK_PKIS: CHEK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -10 % | GSK_PKIS: IKK-alpha % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = -6.72 % | GSK_PKIS: CHEK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -5.85 % | GSK_PKIS: TYK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -5.43 % | GSK_PKIS: CRAF mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -5.23 % | GSK_PKIS: DAPK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -5.13 % | GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -5.09 % | GSK_PKIS: DAPK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -4.84 % | GSK_PKIS: CHEK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -4.58 % | GSK_PKIS: MSK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -4.52 % | GSK_PKIS: PI4K-beta mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -3.85 % | GSK_PKIS: MAPKAPK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -3.46 % | GSK_PKIS: FGFR1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -3.46 % | GSK_PKIS: SPHK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -3 % | GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = -3 % | GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.89 % | GSK_PKIS: NEK7 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.74 % | GSK_PKIS: MAPKAPK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.63 % | GSK_PKIS: CHEK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.61 % | GSK_PKIS: INSR mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.51 % | GSK_PKIS: SPHK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.46 % | GSK_PKIS: TYK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.32 % | GSK_PKIS: CAMK4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.29 % | GSK_PKIS: FYN mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -2.14 % | GSK_PKIS: PAK5 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.93 % | GSK_PKIS: YES mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.67 % | GSK_PKIS: BMX mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.65 % | GSK_PKIS: MSK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.61 % | GSK_PKIS: MAPKAPK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.58 % | GSK_PKIS: PKC-iota mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.39 % | GSK_PKIS: SPHK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.37 % | GSK_PKIS: NEK7 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.32 % | GSK_PKIS: ZAP70 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.17 % | GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.16 % | GSK_PKIS: CDK3/cyclinE mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.15 % | GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.05 % | GSK_PKIS: JAK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1.03 % | GSK_PKIS: CDK1/cyclinB mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -1 % | GSK_PKIS: IKK-epsilon % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = -1 % | GSK_PKIS: TBK1 % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.99 % | GSK_PKIS: SYK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.97 % | GSK_PKIS: IKKA mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.95 % | GSK_PKIS: MELK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.89 % | GSK_PKIS: PAR-1Balpha mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.87 % | GSK_PKIS: PIM2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.84 % | GSK_PKIS: PHKG1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.81 % | GSK_PKIS: SGK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.72 % | GSK_PKIS: AMPKA2 (A2B1G1) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.71 % | GSK_PKIS: AKT3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.64 % | GSK_PKIS: P38gamma mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.63 % | GSK_PKIS: FGFR4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.49 % | GSK_PKIS: MAPKAPK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.48 % | GSK_PKIS: ROS mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.42 % | GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.35 % | GSK_PKIS: CDK2/cyclinE mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.27 % | GSK_PKIS: PKC-beta2 (splice variant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.24 % | GSK_PKIS: PIM2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.22 % | GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.2 % | GSK_PKIS: PRKG1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.16 % | GSK_PKIS: CDK5/p35 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.09 % | GSK_PKIS: CDK5/p35 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.04 % | GSK_PKIS: PTK5 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = -0.02 % | GSK_PKIS: RSK4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0 % | GSK_PKIS: KIT (D816V mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0 % | GSK_PKIS: IKK-beta % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.03 % | GSK_PKIS: MRCKB mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.03 % | GSK_PKIS: MAPK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.04 % | GSK_PKIS: LTK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.05 % | GSK_PKIS: DYRK1A mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.06 % | GSK_PKIS: AKT1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.09 % | GSK_PKIS: CLK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.1 % | GSK_PKIS: CAMK1D mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.13 % | GSK_PKIS: CK1-g3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.16 % | GSK_PKIS: CAMK4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.26 % | GSK_PKIS: PAK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.27 % | GSK_PKIS: ERBB2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.28 % | GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.28 % | GSK_PKIS: PI3K-delta mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.3 % | GSK_PKIS: CLK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.3 % | GSK_PKIS: ITK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.31 % | GSK_PKIS: TBK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.31 % | GSK_PKIS: MARK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.32 % | GSK_PKIS: PRAK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.32 % | GSK_PKIS: BRSK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.33 % | GSK_PKIS: P38delta mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.34 % | GSK_PKIS: SRPK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.38 % | GSK_PKIS: SGK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.4 % | GSK_PKIS: ZAP70 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.41 % | GSK_PKIS: AMPKA1 (A1B1G1) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.42 % | GSK_PKIS: PKC-theta mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.46 % | GSK_PKIS: PKC-iota mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.47 % | GSK_PKIS: INSR mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.48 % | GSK_PKIS: SNF1LK2 (QIK) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.48 % | GSK_PKIS: CK1-g2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.49 % | GSK_PKIS: PIM1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.49 % | GSK_PKIS: ROS mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.5 % | GSK_PKIS: CDK1/cyclinB mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.52 % | GSK_PKIS: PRKD2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.53 % | GSK_PKIS: PAK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.53 % | GSK_PKIS: IRAK4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.54 % | GSK_PKIS: P38delta mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.55 % | GSK_PKIS: KIT (D816V mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.58 % | GSK_PKIS: RSK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.58 % | GSK_PKIS: NEK6 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.6 % | GSK_PKIS: BRSK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.6 % | GSK_PKIS: NEK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.6 % | GSK_PKIS: BLK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.61 % | GSK_PKIS: SRMS mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.62 % | GSK_PKIS: FES mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.65 % | GSK_PKIS: MRCKB mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.7 % | GSK_PKIS: PKC-alpha mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.7 % | GSK_PKIS: DYRK1B mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.71 % | GSK_PKIS: CDK2/cyclinA mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.72 % | GSK_PKIS: PKC-alpha mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.73 % | GSK_PKIS: DYRK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.73 % | GSK_PKIS: PYK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.75 % | GSK_PKIS: PRKD3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.76 % | GSK_PKIS: CK1a mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.77 % | GSK_PKIS: TSSK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.79 % | GSK_PKIS: SRC mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.79 % | GSK_PKIS: TBK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.8 % | GSK_PKIS: PI3K-alpha mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.82 % | GSK_PKIS: CLK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.83 % | GSK_PKIS: YES mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.85 % | GSK_PKIS: CK1-g1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.86 % | GSK_PKIS: PKA mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.86 % | GSK_PKIS: PRKG2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.88 % | GSK_PKIS: PRKG2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.88 % | GSK_PKIS: PAK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.9 % | GSK_PKIS: FES mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.91 % | GSK_PKIS: PRKX mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.96 % | GSK_PKIS: EGFR (L861Q mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.96 % | GSK_PKIS: RSK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.96 % | GSK_PKIS: PRAK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 0.97 % | GSK_PKIS: CDK4/cyclinD mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.01 % | GSK_PKIS: CDK3/cyclinE mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.01 % | GSK_PKIS: PRKD1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.01 % | GSK_PKIS: JNK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.04 % | GSK_PKIS: IRAK4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.05 % | GSK_PKIS: CK1-g1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.06 % | GSK_PKIS: EGFR (T790M mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.07 % | GSK_PKIS: RSK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.07 % | GSK_PKIS: JAK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.08 % | GSK_PKIS: CK1-g2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.09 % | GSK_PKIS: PDK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.1 % | GSK_PKIS: PIM3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.1 % | GSK_PKIS: DYRK1B mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.1 % | GSK_PKIS: NEK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.1 % | GSK_PKIS: PLK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.11 % | GSK_PKIS: TSSK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.12 % | GSK_PKIS: PKC-beta1 (splice variant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.12 % | GSK_PKIS: PKC-theta mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.13 % | GSK_PKIS: DYRK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.13 % | GSK_PKIS: JAK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.18 % | GSK_PKIS: CAMK1D mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.22 % | GSK_PKIS: MSK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.22 % | GSK_PKIS: PAK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.23 % | GSK_PKIS: AKT2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.24 % | GSK_PKIS: NEK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.25 % | GSK_PKIS: PRKD1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.25 % | GSK_PKIS: RSK4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.26 % | GSK_PKIS: DYRK1A mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.27 % | GSK_PKIS: PIM1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.27 % | GSK_PKIS: JAK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.28 % | GSK_PKIS: MEK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.28 % | GSK_PKIS: SRMS mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.29 % | GSK_PKIS: PAK6 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.3 % | GSK_PKIS: TSSK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.3 % | GSK_PKIS: BRK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.3 % | GSK_PKIS: MSK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.32 % | GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.34 % | GSK_PKIS: ALK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.35 % | GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.36 % | GSK_PKIS: AKT1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.37 % | GSK_PKIS: ARK5 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.37 % | GSK_PKIS: SRPK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.38 % | GSK_PKIS: CLK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.39 % | GSK_PKIS: JAK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.41 % | GSK_PKIS: PASK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.41 % | GSK_PKIS: MSSK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.42 % | GSK_PKIS: DCAMKL2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.44 % | GSK_PKIS: PASK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.44 % | GSK_PKIS: MEK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.45 % | GSK_PKIS: AKT2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.46 % | GSK_PKIS: AMPKA1 (A1B1G1) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.47 % | GSK_PKIS: HIPK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.49 % | GSK_PKIS: MAP4K4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.5 % | GSK_PKIS: MARK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.5 % | GSK_PKIS: RSK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.5 % | GSK_PKIS: CDK4/cyclinD mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.51 % | GSK_PKIS: CAMK2D mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.51 % | GSK_PKIS: CDK6/cyclinD3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.52 % | GSK_PKIS: RSK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.53 % | GSK_PKIS: GSK3A mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.54 % | GSK_PKIS: P38beta mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.54 % | GSK_PKIS: P38gamma mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.57 % | GSK_PKIS: BTK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.59 % | GSK_PKIS: FLT3 (D835Y mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.59 % | GSK_PKIS: RSK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.59 % | GSK_PKIS: SGK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.6 % | GSK_PKIS: EGFR (T790M mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.67 % | GSK_PKIS: BTK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.67 % | GSK_PKIS: BMX mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.69 % | GSK_PKIS: MARK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.72 % | GSK_PKIS: PRKD3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.72 % | GSK_PKIS: TSSK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.75 % | GSK_PKIS: MRCKA mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.76 % | GSK_PKIS: BRK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.78 % | GSK_PKIS: NEK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.82 % | GSK_PKIS: MAP4K2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.84 % | GSK_PKIS: FER mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.87 % | GSK_PKIS: LTK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.87 % | GSK_PKIS: ITK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.88 % | GSK_PKIS: GSK3B mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.88 % | GSK_PKIS: PRKD2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.95 % | GSK_PKIS: PKC-gamma mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.95 % | GSK_PKIS: CDK2/cyclinA mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 1.99 % | GSK_PKIS: SNF1LK2 (QIK) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2 % | GSK_PKIS: PKC-gamma mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.03 % | GSK_PKIS: PLK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.03 % | GSK_PKIS: TXK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.04 % | GSK_PKIS: MRCKA mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.05 % | GSK_PKIS: IRR mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.05 % | GSK_PKIS: EGFR (L861Q mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.06 % | GSK_PKIS: SNF1LK (SIK) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.07 % | GSK_PKIS: TEC mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.12 % | GSK_PKIS: CK1a mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.12 % | GSK_PKIS: MAPK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.14 % | GSK_PKIS: PKC-eta mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.16 % | GSK_PKIS: Aurora-A mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.25 % | GSK_PKIS: MAPK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.27 % | GSK_PKIS: SNF1LK (SIK) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.28 % | GSK_PKIS: MSSK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.29 % | GSK_PKIS: MELK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.34 % | GSK_PKIS: BLK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.37 % | GSK_PKIS: GRK6 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.37 % | GSK_PKIS: PDK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.41 % | GSK_PKIS: P38alpha mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.44 % | GSK_PKIS: PI3K-alpha mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.45 % | GSK_PKIS: IGF1R mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.48 % | GSK_PKIS: MST4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.52 % | GSK_PKIS: EGFR (L858R mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.55 % | GSK_PKIS: PAR-1Balpha mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.63 % | GSK_PKIS: CAMK2D mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.67 % | GSK_PKIS: JNK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.68 % | GSK_PKIS: GRK6 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.69 % | GSK_PKIS: PKC-eta mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.74 % | GSK_PKIS: MST4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.75 % | GSK_PKIS: SYK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.77 % | GSK_PKIS: IKKE mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.78 % | GSK_PKIS: AKT3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.79 % | GSK_PKIS: MAPK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.79 % | GSK_PKIS: PAK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.83 % | GSK_PKIS: IKKB mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.93 % | GSK_PKIS: PKA mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.93 % | GSK_PKIS: CK1-g3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.93 % | GSK_PKIS: PAK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.94 % | GSK_PKIS: PHKG1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.96 % | GSK_PKIS: MER mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 2.98 % | GSK_PKIS: PTK5 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.01 % | GSK_PKIS: MINK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.03 % | GSK_PKIS: CDK2/cyclinE mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.05 % | GSK_PKIS: P38alpha mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.07 % | GSK_PKIS: PHKG2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.08 % | GSK_PKIS: PRKG1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.09 % | GSK_PKIS: IKKB mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.09 % | GSK_PKIS: FGFR3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.11 % | GSK_PKIS: MER mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.12 % | GSK_PKIS: BRSK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.18 % | GSK_PKIS: PRKX mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.23 % | GSK_PKIS: PI3K-delta mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.24 % | GSK_PKIS: NEK6 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.25 % | GSK_PKIS: FGFR2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.26 % | GSK_PKIS: FGFR1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.32 % | GSK_PKIS: IKKE mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.34 % | GSK_PKIS: TNK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.37 % | GSK_PKIS: MAP4K4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.39 % | GSK_PKIS: IRR mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.46 % | GSK_PKIS: MINK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.47 % | GSK_PKIS: MARK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.52 % | GSK_PKIS: PIM3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.57 % | GSK_PKIS: PHKG2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.59 % | GSK_PKIS: EGFR (T790M-L858R mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.61 % | GSK_PKIS: SGK3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.66 % | GSK_PKIS: EPHB3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.68 % | GSK_PKIS: ALK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.69 % | GSK_PKIS: MST1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.74 % | GSK_PKIS: SGK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.74 % | GSK_PKIS: NEK9 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.75 % | GSK_PKIS: CSK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.77 % | GSK_PKIS: CAMK2A mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.85 % | GSK_PKIS: FER mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.91 % | GSK_PKIS: TEC mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 3.95 % | GSK_PKIS: NEK9 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.01 % | GSK_PKIS: CSK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.18 % | GSK_PKIS: ARK5 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.21 % | GSK_PKIS: FGFR4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.24 % | GSK_PKIS: CAMK2A mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.24 % | GSK_PKIS: MNK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.31 % | GSK_PKIS: p70s6K1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.31 % | GSK_PKIS: EGFR (T790M-L858R mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.58 % | GSK_PKIS: CRAF mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.62 % | GSK_PKIS: JAK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.72 % | GSK_PKIS: FYN mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.74 % | GSK_PKIS: IKKA mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.76 % | GSK_PKIS: HCK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.8 % | GSK_PKIS: GRK7 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.83 % | GSK_PKIS: GSK3A mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.86 % | GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.89 % | GSK_PKIS: MST2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 4.9 % | GSK_PKIS: HIPK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.04 % | GSK_PKIS: IGF1R mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.1 % | GSK_PKIS: MST2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.12 % | GSK_PKIS: SGK3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.13 % | GSK_PKIS: TXK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.18 % | GSK_PKIS: FGR mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.19 % | GSK_PKIS: p70s6K1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.21 % | GSK_PKIS: MAP4K2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.24 % | GSK_PKIS: PI4K-beta mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.32 % | GSK_PKIS: ROCK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.42 % | GSK_PKIS: EGFR (L858R mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.51 % | GSK_PKIS: LRRK2 (G2019S mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.62 % | GSK_PKIS: RON mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.68 % | GSK_PKIS: FGR mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.71 % | GSK_PKIS: MKNK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.84 % | GSK_PKIS: SRC mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.87 % | GSK_PKIS: LCK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.94 % | GSK_PKIS: RON mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 5.96 % | GSK_PKIS: BRSK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6 % | GSK_PKIS: IKK-beta % inhibition at 1 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.09 % | GSK_PKIS: ABL1 (E255K mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.14 % | GSK_PKIS: P38beta mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.29 % | GSK_PKIS: EPHB3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.29 % | GSK_PKIS: FLT3 (D835Y mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.45 % | GSK_PKIS: TTK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.49 % | GSK_PKIS: GSK3B mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.75 % | GSK_PKIS: DCAMKL2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.8 % | GSK_PKIS: TTK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 6.95 % | GSK_PKIS: FGFR3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7 % | GSK_PKIS: ERBB2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.28 % | GSK_PKIS: HCK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.33 % | GSK_PKIS: HIPK4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.33 % | GSK_PKIS: EGFR mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.41 % | GSK_PKIS: ABL1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.42 % | GSK_PKIS: CDK6/cyclinD3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.64 % | GSK_PKIS: FLT4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.66 % | GSK_PKIS: LYN B (splice variant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 7.89 % | GSK_PKIS: Aurora-B mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8 % | GSK_PKIS: EGFR mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8 % | GSK_PKIS: Mer Kinase % inhibition at 10 uM [UNC Frye lab] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.1 % | GSK_PKIS: PYK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.2 % | GSK_PKIS: ROCK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.2 % | GSK_PKIS: LRRK2 (G2019S mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.38 % | GSK_PKIS: Aurora-A mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.47 % | GSK_PKIS: LCK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.59 % | GSK_PKIS: PAK5 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.78 % | GSK_PKIS: LRRK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.88 % | GSK_PKIS: MST1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 8.89 % | GSK_PKIS: FGFR2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 9.12 % | GSK_PKIS: BRAF mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 9.23 % | GSK_PKIS: BRAF (V599E mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 9.23 % | GSK_PKIS: LRRK2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 9.63 % | GSK_PKIS: AXL mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 9.67 % | GSK_PKIS: ERBB4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 10.04 % | GSK_PKIS: LYN A (splice variant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 10.08 % | GSK_PKIS: EPHA3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 10.32 % | GSK_PKIS: Aurora-C mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 10.59 % | GSK_PKIS: TYRO3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 11.71 % | GSK_PKIS: PDGFRA (D842V mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 12.11 % | GSK_PKIS: ROCK1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 12.21 % | GSK_PKIS: MNK2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 12.22 % | GSK_PKIS: BRAF mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 13.79 % | GSK_PKIS: BRAF (V599E mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 13.82 % | GSK_PKIS: TNK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 13.88 % | GSK_PKIS: EPHA3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 13.88 % | GSK_PKIS: HIPK4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 14.31 % | GSK_PKIS: ABL1 (E255K mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 14.82 % | GSK_PKIS: ARG mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.23 % | GSK_PKIS: LYN B (splice variant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.29 % | GSK_PKIS: ERBB4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.45 % | GSK_PKIS: PAK6 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.58 % | GSK_PKIS: GRK7 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.58 % | GSK_PKIS: Aurora-B mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.69 % | GSK_PKIS: EPHB4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.72 % | GSK_PKIS: MET mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 15.75 % | GSK_PKIS: MKNK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 16.16 % | GSK_PKIS: MUSK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 16.26 % | GSK_PKIS: FLT4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 18.3 % | GSK_PKIS: ROCK1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 18.34 % | GSK_PKIS: ABL1 (Y253F mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 20.35 % | GSK_PKIS: TRKC mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 20.46 % | GSK_PKIS: PDGFRA (D842V mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 20.83 % | GSK_PKIS: LYN A (splice variant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 21.38 % | GSK_PKIS: TRKB mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 21.38 % | GSK_PKIS: TYRO3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 23.75 % | GSK_PKIS: ABL1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 25.52 % | GSK_PKIS: AXL mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 26.59 % | GSK_PKIS: ABL1 (Y253F mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 27.41 % | GSK_PKIS: MET mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 27.48 % | GSK_PKIS: EPHB4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 30.31 % | GSK_PKIS: TRKC mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 30.67 % | GSK_PKIS: TRKB mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 30.77 % | GSK_PKIS: TRKA mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 31.15 % | GSK_PKIS: MUSK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 34 % | GSK_PKIS: ABL1 (H396P mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 35.6 % | GSK_PKIS: RET (V804L mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 36.42 % | GSK_PKIS: FLT1 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 37.43 % | GSK_PKIS: FLT3 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 37.45 % | GSK_PKIS: Aurora-C mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 40.39 % | GSK_PKIS: PDGFRB mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 40.57 % | GSK_PKIS: ABL1 (T315I mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 43.73 % | GSK_PKIS: TRKA mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 43.83 % | GSK_PKIS: FLT1 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 44.49 % | GSK_PKIS: EPHB2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 44.77 % | GSK_PKIS: ARG mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 44.83 % | GSK_PKIS: FMS mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 46.17 % | GSK_PKIS: TIE2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 46.79 % | GSK_PKIS: LOK mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 48.04 % | GSK_PKIS: FLT3 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 48.43 % | GSK_PKIS: ABL1 (Q252H mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 48.59 % | GSK_PKIS: ABL1 (M351T mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 49.4 % | GSK_PKIS: EPHA2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 51.26 % | GSK_PKIS: ABL1 (T315I mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 51.75 % | GSK_PKIS: ABL1 (H396P mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 52.27 % | GSK_PKIS: EPHA4 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 53.49 % | GSK_PKIS: RET (Y791F mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 54.63 % | GSK_PKIS: FMS mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 55.68 % | GSK_PKIS: TIE2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 55.82 % | GSK_PKIS: KDR mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 56.33 % | GSK_PKIS: PDGFRB mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 57.82 % | GSK_PKIS: LOK mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 57.85 % | GSK_PKIS: ABL1 (M351T mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 58.57 % | GSK_PKIS: KIT (T6701 mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 60.79 % | GSK_PKIS: ABL1 (Q252H mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 62.99 % | GSK_PKIS: EPHB2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 63.15 % | GSK_PKIS: RET (V804L mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 65.61 % | GSK_PKIS: KIT (V560G mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 65.73 % | GSK_PKIS: EPHA2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 66.82 % | GSK_PKIS: KDR mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 69.85 % | GSK_PKIS: KIT (T6701 mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 72.35 % | GSK_PKIS: EPHA4 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 72.85 % | GSK_PKIS: RET mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 74.14 % | GSK_PKIS: KIT (V560G mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 74.57 % | GSK_PKIS: RET (Y791F mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 75.71 % | GSK_PKIS: PDGFRA (T674I mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 78 % | GSK_PKIS: DDR2 mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 79.88 % | GSK_PKIS: RET mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 80.25 % | GSK_PKIS: DDR2 mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 86.58 % | GSK_PKIS: PDGFRA (V561D mutant) mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 87.51 % | GSK_PKIS: KIT mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 88.48 % | GSK_PKIS: PDGFRA mean inhibition at 0.1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 93.05 % | GSK_PKIS: KIT mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 94.47 % | GSK_PKIS: PDGFRA (V561D mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 96.81 % | GSK_PKIS: PDGFRA mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Inhibition (binding) | = 100.05 % | GSK_PKIS: PDGFRA (T674I mutant) mean inhibition at 1 uM [Nanosyn] | ChEMBL. | No reference |
| Potency (functional) | 12.5385 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL243907
- PubChem: 10160775
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.